Sysco Chicago Donates $10,000 and 2,500 Turkeys to the Northern Illinois Food Bank for Holidays
CHICAGO, Nov. 13, 2024 (GLOBE NEWSWIRE) — Today, Sysco Corporation (NYSE:SYY), the world’s largest food distributor, presented a check for […]
RGC Resources, Inc. Reports 2024 Earnings
ROANOKE, Va., Nov. 13, 2024 (GLOBE NEWSWIRE) — RGC Resources, Inc. (Nasdaq: RGCO) announced consolidated Company earnings of $11,760,896, or […]
Orchid Island Capital Announces November 2024 Monthly Dividend and October 31, 2024 RMBS Portfolio Characteristics
November 2024 Monthly Dividend of $0.12 Per Share of Common Stock Estimated Book Value Per Share as of November 8, 2024 of […]
NEXGEL Reports Record Third Quarter 2024 Revenue of $2.94 Million, an Increase of 141% Year-Over-Year and 104% Sequentially
Quarterly revenue growth driven by a sequential increase of 99% in branded consumer products and 103% in contract manufacturing Gross […]
Calidi Biotherapeutics Announces Proposed Public Offering
SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) — Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage […]
Supernus Pharmaceuticals to Participate in the 2024 Jefferies London Healthcare Conference
ROCKVILLE, Md., Nov. 13, 2024 (GLOBE NEWSWIRE) — Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and […]
Jasper Therapeutics to Participate at Upcoming Investor Conferences
REDWOOD CITY, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) — Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company […]
Natural Alternatives International, Inc. Announces 2025 Q1 Results
CARLSBAD, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) — Natural Alternatives International, Inc. (“NAI”) (Nasdaq: NAII), a leading formulator, manufacturer, and […]
Springbig Announces Third Quarter 2024 Financial Results and Amendment to its $6.4 million Convertible Notes and $1.6 million Term Loan
Company achieves positive Adjusted EBITDA* for the third consecutive quarter, reaching $0.9 million year-to-date, a $4.3 million improvement year-on-year Third-quarter […]
Sutro Biopharma Reports Third Quarter 2024 Financial Results and Business Highlights
– Expects to deliver three Investigational New Drug (IND) applications in next three years based on next-generation ADC technology – […]
